Virology Department, Faculty of Veterinary Medicine, Ankara University, Ankara 06110, Turkey.
Virology Unit, Department of Medical Microbiology, Faculty of Medicine, Hacettepe University, Ankara 06100, Turkey.
Viruses. 2019 Jan 17;11(1):75. doi: 10.3390/v11010075.
Crimean Congo hemorrhagic fever virus (CCHFV) is the causative agent of a globally-spread tick-borne zoonotic infection, with an eminent risk of fatal human disease. The imminent public health threat posed by the disseminated virus activity and lack of an approved therapeutic make CCHFV an urgent target for vaccine development. We described the construction of a DNA vector expressing a nucleocapsid protein (N) of CCHFV (pV-N13), and investigated its potential to stimulate the cytokine and total/specific antibody responses in BALB/c and a challenge experiment in IFNAR mice. Because of a lack of sufficient antibody stimulation towards the N protein, we have selected cluster of differentiation 24 (CD24) protein as a potential adjuvant, which has a proliferative effect on B and T cells. Overall, our N expressing construct, when administered solely or in combination with the pCD24 vector, elicited significant cellular and humoral responses in BALB/c, despite variations in the particular cytokines and total antibodies. However, the stimulated antibodies produced as a result of the N protein expression have shown no neutralizing ability in the virus neutralization assay. Furthermore, the challenge experiments revealed the protection potential of the N expressing construct in an IFNAR mice model. The cytokine analysis in the IFNAR mice showed an elevation in the IL-6 and TNF-alpha levels. In conclusion, we have shown that targeting the S segment of CCHFV can be considered for a practical way to develop a vaccine against this virus, because of its ability to induce an immune response, which leads to protection in the challenge assays in the interferon (IFN)-gamma defective mice models. Moreover, CD24 has a prominent immunologic effect when it co-delivers with a suitable foreign gene expressing vector.
克里米亚-刚果出血热病毒(CCHFV)是一种全球性传播的蜱传动物传染病原体,具有导致人类疾病致命的显著风险。该病毒的广泛传播活动和缺乏批准的治疗方法,构成了当前对公共健康的严重威胁,因此 CCHFV 成为疫苗开发的紧急目标。我们描述了一种表达 CCHFV 核衣壳蛋白(N)的 DNA 载体(pV-N13)的构建,并研究了其在 BALB/c 中的细胞因子和总/特异性抗体反应以及 IFNAR 小鼠中的挑战实验中的潜力。由于针对 N 蛋白的抗体刺激不足,我们选择了分化簇 24(CD24)蛋白作为潜在的佐剂,该佐剂对 B 和 T 细胞具有增殖作用。总体而言,我们的 N 表达构建体,无论是单独给药还是与 pCD24 载体联合给药,都在 BALB/c 中引起了显著的细胞和体液反应,尽管细胞因子和总抗体的变化有所不同。然而,由于 N 蛋白表达而产生的刺激抗体在病毒中和测定中没有显示出中和能力。此外,挑战实验揭示了 N 表达构建体在 IFNAR 小鼠模型中的保护潜力。IFNAR 小鼠中的细胞因子分析显示 IL-6 和 TNF-alpha 水平升高。总之,我们已经表明,针对 CCHFV 的 S 片段的靶向可以被认为是开发针对该病毒的疫苗的一种实用方法,因为它能够诱导免疫反应,从而在 IFN-γ 缺陷型小鼠模型的挑战实验中导致保护。此外,当与合适的外源基因表达载体共同给药时,CD24 具有显著的免疫效应。